Karen MacCurdy Thompson - FCAPhO Recipient 2018

I started working in oncology at The Moncton Hospital in the early 1990’s and joined CAPHO on the advice of a colleague. I served on the Education Committee and was involved in planning
the annual conferences in the early 1990’s. I have been a speaker at the conferences and have participated in educational sessions on line at various times. I have reviewed abstracts and
participated in the selections of those chosen for poster presentations at the conference(s). I recently put my name forward to be a member of The Specialization Task Force.

A colleague and myself were the innovators for getting pharmacy involved in the area of oncology at our hospital. I have written pharmacy directives for monitoring patients on Colony Stimulating Factors, educated pharmacy staff and oncology personnel on treatment regimens and cancer diseases; educated hundreds of patients and families on cancer treatments and have reached beyond hospital walls to community pharmacies at the time of the patient being discharged. My experience with bone marrow transplant is limited but we do care for patients who have undergone an autologous transplant at our institution. I have been involved in
developing Clinical Order Sets for Post-Autologous Transplant Patients, Oncology Admission Order Sets and I play a significant role in providing supportive care to our patients.

I have participated in Research as the pharmacist on the team approving studies, record keeping, retrieval of medication and other tasks associated with the Research Protocol. The 1997 Canadian Society of Hospital Pharmacists (CSHP) Guidelines suggest that “research” can be used to describe many endeavors in institutional pharmacy practice which can include literature reviews, descriptive studies, basic pharmaceutical sciences such as the testing of medication-administration modalities and evaluating the efficacy and safety of drugs. I have contributed to Research in many of the above described situations. The Filgrastim Monitoring Service Program was research I conducted with a pharmacy resident and continued this program after his departure from our hospital. The primary goal was to reduce the number of injections/doses of filgrastim people were receiving post their treatment. Prior to the start of this pilot project, the use of these expensive agents was monitored by the oncologist and the average number of doses of filgrastim was fourteen and patients had on average eight vials
remaining at home on completion of their chemotherapy. The project and monitoring reduced the usage down to an average of 8 and decreased the wastage of at home vials. A cost saving was acknowledged and more importantly the number of injections that patients had to administer was reduced.